Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Live...
Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
About this item
Full title
Author / Creator
Wang, Ling-Zhi , Ramírez, Jacqueline , Yeo, Winnie , Chan, Mei-Yi Michelle , Thuya, Win-Lwin , Lau, Jie-Ying Amelia , Wan, Seow-Ching , Wong, Andrea Li-Ann , Zee, Ying-Kiat , Lim, Robert , Lee, Soo-Chin , Ho, Paul C. , Lee, How-Sung , Chan, Anthony , Ansher, Sherry , Ratain, Mark J. and Goh, Boon-Cher
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. The pharmacokinetics of belino...
Alternative Titles
Full title
Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_1327961408
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1327961408
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0054522
